nach oben

Annals of Hematology

Erschienen in:

01.12.2009 | Original Article

Downregulation of telomerase activity in human promyelocytic cell line using RNA interference

verfasst von: E. Miri-Moghaddam, A. Deezagi, Z. S. Soheili

Erschienen in: Annals of Hematology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Telomerase is a ribonucleoprotein complex. It consists of two main components, human telomerase reverse transcriptase (hTERT) and human telomerase RNA. High telomerase activity is present in most malignant cells, but it is barely detectable in majority of somatic cells. The direct correlation between telomerase reactivation and carcinogens has made hTERT a key target for anticancer therapeutic studies. In this study, for the first time, we evaluated the ability of the new generation of short interfering RNA (siRNA) to regulate telomerase activity in the human promyelocytic leukemia cell line (HL-60). Transient transfection cell line by hTERT siRNAs resulted in statistically significant suppression of hTERT messenger RNAs which were detected by quantitative real-time polymerase chain reaction, while the expressed hTERT protein levels were measured by flow cytometry. The results of telomeric repeat amplification protocol showed that telomerase activity was significantly reduced upon transfection of the HL-60 cell line with hTERT siRNAs. The results of this study showed that telomerase activity and cell proliferation were efficiently inhibited in the hTERT siRNA-treated leukemic cell line.

Zakian VA (1995) Telomeres: beginning to understand the end. Science 270:1601–1607. doi:10.1126/science.270.5242.1601 CrossRefPubMed

McEachern MJ, Krauskopf A, Blackburn EH (2000) Telomeres and their control. Annu Rev Genet 34:331–358. doi:10.1146/annurev.genet.34.1.331 CrossRefPubMed

Oulton R, Harrington L (2000) Telomeres, telomerase, and cancer: life on the edge of genomic stability. Curr Opin Oncol 12:74–81. doi:10.1097/00001622-200001000-00013 CrossRefPubMed

Hoeijmakers JHJ (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374. doi:10.1038/35077232 CrossRefPubMed

Wright WE, Shay JW (1992) The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 27:383–389. doi:10.1016/0531-5565(92)90069-C CrossRefPubMed

Blackburn EH (1992) Telomerases. Annu Rev Biochem 61:113–129. doi:10.1146/annurev.bi.61.070192.000553 CrossRefPubMed

Greider CW (1996) Telomere length regulation. Annu Rev Biochem 65:337–365. doi:10.1146/annurev.bi.65.070196.002005 CrossRefPubMed

Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE et al (1997) Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17:498–502. doi:10.1038/ng1297-498 CrossRefPubMed

Nakayama JI, Tahara H, Tahara E, Saito M, Ito K, Nakamura H et al (1998) Telomerase activation by HTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18:65–68. doi:10.1038/ng0198-65 CrossRefPubMed

10.

Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279:349–352. doi:10.1126/science.279.5349.349 CrossRefPubMed

11.

Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015. doi:10.1126/science.7605428 CrossRefPubMed

12.

Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M et al (1999) Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21:111–114. doi:10.1038/5056 CrossRefPubMed

13.

Zhang TC, Schmitt MT, Mumford JL (2003) Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 24:1811–1817. doi:10.1093/carcin/bgg141 CrossRefPubMed

14.

Liu L, Berletch JB, Green JG, Pate MS, Andrews LG, Tollefsbol TO (2004) Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol Cancer Ther 3:1003–1009PubMed

15.

Liu J-J, Wu X-Y, Peng J, Pan X-L, Lu H-L (2004) Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 83:691–695. doi:10.1007/s00277-004-0919-y CrossRefPubMed

16.

Yamaguchi T, Takahashi H, Harada Y, Yoshikawa M, Iyono S, Inomata M et al (2004) Telomere shortening in human HL60 cells by treatment with deoxyguanosine analogs. Nucleic Acids Symp Ser 48:187–188. doi:10.1093/nass/48.1.187 CrossRef

17.

Pizzimenti S, Briatore F, Laurora S, Toaldo C, Maggio M, De Grandi M et al (2006) 4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic Biol Med 40:1578–1591. doi:10.1016/j.freeradbiomed.2005.12.024 CrossRefPubMed

18.

Wang F, Sun L, Sun H, Fan Q, Le X, Zhang Q (2007) Inhibition hTERT antisense oligodeoxynucleotide changes proliferation and telomerase activity of HL-60 cell. Life Sci J 4:17–21

19.

Hannon GJ (2002) RNA interference. Nature 418:244–251. doi:10.1038/418244a CrossRefPubMed

20.

Hammond SM, Caudy AA, Hannon GJ (2001) Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2:110–119. doi:10.1038/35052556 CrossRefPubMed

21.

Zhang PH, Zou L, Tu ZG (2006) RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 131:143–149. doi:10.1016/j.jss.2005.09.017 CrossRefPubMed

22.

Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S et al (2007) Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol 73:1703–1714. doi:10.1016/j.bcp. 2007.01.035 CrossRefPubMed

23.

De Souza Nascimento P, Alves G, Fiedler W (2006) Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncol Rep 16:423–428PubMed

24.

Zheng JN, Sun YF, Pei DS, Liu JJ, Chen JC, Li W, Sun XQ, Shi QD, Han RF, Ma TX (2006) Inhibition of proliferation and induction of apoptosis in human renal carcinoma cells by anti-telomerase small interfering RNAs. Acta Biochim Biophys Sin (Shanghai) 38:500–506. doi:10.1111/j.1745-7270.2006.00182.x CrossRef

25.

Shammas MA, Koley H, Batchu RB, Bertheau RC, Protopopov A, Munshi NC, Goyal RK (2005) Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 4:24. doi:10.1186/1476-4598-4-24 CrossRefPubMed

26.

Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U et al (2004) siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25:1065–1071PubMed

27.

Tebes SJ, Johnson NC, Fiorica JV, Kruk PA (2005) Inhibition of telomerase in ovarian cancer using siRNA technology. J Clin Oncol 23:3182 Meeting abstracts

28.

Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330. doi:10.1038/nbt936 CrossRefPubMed

29.

Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159. doi:10.1016/0003-2697(87)90021-2 CrossRefPubMed

30.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408CrossRefPubMed

31.

Lin Y, Miyamoto N, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y (1996) Telomerase activity in human bladder cancer. Clin Cancer Res 2:929–932PubMed

32.

Ohyashki J, Sashida G, Tauchi T, Ohyashiki K (2002) Telomeres and telomerase in hematologic neoplasia. Oncogene 21:680–687. doi:10.1038/sj.onc.1205075 CrossRef

33.

Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M (2000) Sp-1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28:669–677. doi:10.1093/nar/28.3.669 CrossRefPubMed

34.

Yamada O, Ozaki K, Nakatake M, Akiyama M, Kawauchi K, Matsuoka R (2008) Multistep regulation of telomerase during differentiation of HL-60 cells. J Leukoc Biol 83:1–9CrossRef

35.

Guittat L, Alberti P, Gomez D, De Cian A, Pennarun G, Lemarteleur T et al (2004) Targeting human telomerase for cancer therapeutics. Cytotechnology 45:75–90. doi:10.1007/s10616-004-5127-z CrossRefPubMed

36.

Saretzki G (2003) Telomerase inhibition as cancer therapy. Cancer Lett 194:209. doi:10.1016/S0304-3835(02)00708-5 CrossRefPubMed

37.

Wang Q, Liu M, Kozasa T, Rothestein JD, Sternweis PC, Neubig RR (2004) Ribozyme and siRNA-mediated suppression of RGS-containing RhoGEF proteins. Methods Enzymol 389:244–265. doi:10.1016/S0076-6879(04)89015-3 CrossRefPubMed

38.

Lu PY, Xie FY, Woodle MC (2003) siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther 5:225–234PubMed

39.

Kosciolek BA, Kalantidis K, Tabler M, Rowley PT (2003) Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2:209–216PubMed

40.

Hu B, Insel RA (1999) Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of telomerase catalytic subunit. Eur J Immunol 29:3745–3753. doi:10.1002/(SICI)1521-4141(199911)29:11<3745::AID-IMMU3745>3.0.CO;2-1 CrossRefPubMed

41.

Nowak T, Januszkiewicz D, Zawada M, Pernak M, Lewandowski K, Rembowska J et al (2006) Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase. Oncol Rep 16:301–305PubMed

42.

Casillas MA Jr, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO (2003) Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 316:57–65. doi:10.1016/S0378-1119(03)00739-X CrossRefPubMed

43.

Zou L, Zhang P, Luo C, Tu Z (2006) shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 57:328–334. doi:10.1007/s00280-005-0056-x CrossRefPubMed

44.

Zou L, Zhang PH, Luo CL, Tu ZG (2005) Transcript regulation of human telomerase reverse transcriptase by c-myc and mad1. Acta Biochim Biophys Sin (Shanghai) 37:32–38CrossRef

45.

Lai SR, Cunningham AP, Huynh VQ, Andrews LG, Tollefsbol TO (2007) Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp Cell Res 313:322–330. doi:10.1016/j.yexcr.2006.10.014 CrossRefPubMed

46.

Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS, Chung WS (2005) hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 79:267–273. doi:10.1002/ajh.20394 CrossRefPubMed

Titel: Downregulation of telomerase activity in human promyelocytic cell line using RNA interference
verfasst von: E. Miri-Moghaddam
A. Deezagi
Z. S. Soheili
Publikationsdatum: 01.12.2009
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 12/2009
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-009-0748-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2009

Therapeutic implication of BAL in patients with neutropenia

Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma

Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract

Imatinib in breast milk

The Cretan type of nondeletional hereditary persistence of fetal hemoglobin in an Iranian family